The COSTIM bioassay: a novel potency test for dendritic cells

Area of Science:

• Immunology
• Cellular Biology
• Biotechnology

Background:

• Dendritic cells (DCs) are crucial in immunotherapy, necessitating robust quality control for clinical applications.
• Current methods like mixed lymphocyte reaction (MLR) and immunophenotyping have limitations in assessing DC potency.
• Standardized lot-release testing is imperative for dendritic cell products used in cancer immunotherapy.

Purpose of the Study:

• To develop and validate a novel functional potency assay for dendritic cell products.
• To establish a reliable and efficient quality control method for dendritic cell manufacturing.
• To offer an improved alternative to existing potency assays for dendritic cells.

Main Methods:

• Development of the COSTIM bioassay, a functional test measuring co-stimulatory activity.
• Utilizing T-cell stimulation with a sub-optimal anti-CD3 antibody concentration.
• Assessing T-cell proliferation dependent on accessory cells, such as dendritic cells, for co-stimulation.

Main Results:

• The COSTIM bioassay selectively measures the functional co-stimulatory capacity of dendritic cells.
• This novel assay provides superior quality control compared to the traditional MLR assay.
• The COSTIM bioassay is a rapid test, completed in less than 2 days.

Conclusions:

• The COSTIM bioassay is a validated, functional potency test suitable for lot-release of dendritic cell products.
• This assay enhances the quality control of dendritic cells for immunotherapy and clinical trials.
• The COSTIM bioassay offers a more efficient and reliable method for assessing dendritic cell potency.